Axonics r-SNM System is an implantable neuromodulation device. Credit: Business Wire.

US-based Axonics Modulation Technologies has obtained the European CE-Mark approval for magnetic resonance imaging (MRI) conditional labelling of its rechargeable Sacral Neuromodulation (r-SNM) System.

The labelling covers 1.5T and 3T full-body MRI, eliminating the need for patients to undergo surgical removal of their neurostimulator before undergoing an MRI scan on any part below the head.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Axonics r-SNM System received the initial CE-Mark in June 2016 to treat urinary and faecal dysfunction.

“The miniaturised device is said to have the potential to last a minimum of 15 years in the body. It also features quick, safe charging capability and a patient-friendly wireless remote control.”

The first faecal incontinence patients were implanted at the University Hospital Southampton NHS Foundation Trust in the UK in December 2016.

Axonics Modulation Technologies chief medical officer Karen Noblett said: “Full-body MRI labelling is critical to patients who need, or may anticipate needing, magnetic resonance imaging.

“This new expanded labelling eliminates a major concern for both groups of patients and will allow more patients to choose SNM to treat their urinary and bowel dysfunction without compromising their quality of life.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The Axonics r-SNM System is an implantable neuromodulation device that controls the sacral nerve activity to treat overactive bladders (OAB), faecal incontinence and urinary retention.

The miniaturised device is said to have the potential to last a minimum of 15 years in the body. It also features quick, safe charging capability and a patient-friendly wireless remote control.

Axonics Modulation Technologies CEO Raymond Cohen said: “This authorisation of full-body MRI scans in Europe is another important milestone for Axonics, differentiating our technology from the competitive system and further demonstrating the foresight of our engineers and our commitment to invest the time and capital to provide the best possible SNM solution for patients, clinicians and the healthcare system.”

The company is also seeking the US regulatory approval for full body MRI conditional labelling.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact